View Item 

Show simple item record

Disclosing genetic risk for Alzheimer’s dementia to individuals with mild cognitive impairment
dc.contributor.authorChristensen, Kurt D.
dc.contributor.authorKarlawish, Jason
dc.contributor.authorRoberts, J. Scott
dc.contributor.authorUhlmann, Wendy R.
dc.contributor.authorHarkins, Kristin
dc.contributor.authorWood, Elisabeth M.
dc.contributor.authorObisesan, Thomas O.
dc.contributor.authorLe, Lan Q.
dc.contributor.authorCupples, L. Adrienne
dc.contributor.authorZoltick, Emilie S.
dc.contributor.authorJohnson, Megan S.
dc.contributor.authorBradbury, Margaret K.
dc.contributor.authorWaterston, Leo B.
dc.contributor.authorChen, Clara A.
dc.contributor.authorFeldman, Sara
dc.contributor.authorPerry, Denise L.
dc.contributor.authorGreen, Robert C.
dc.date.accessioned2020-04-02T18:39:19Z
dc.date.availableWITHHELD_10_MONTHS
dc.date.available2020-04-02T18:39:19Z
dc.date.issued2020
dc.identifier.citationChristensen, Kurt D.; Karlawish, Jason; Roberts, J. Scott; Uhlmann, Wendy R.; Harkins, Kristin; Wood, Elisabeth M.; Obisesan, Thomas O.; Le, Lan Q.; Cupples, L. Adrienne; Zoltick, Emilie S.; Johnson, Megan S.; Bradbury, Margaret K.; Waterston, Leo B.; Chen, Clara A.; Feldman, Sara; Perry, Denise L.; Green, Robert C. (2020). "Disclosing genetic risk for Alzheimer’s dementia to individuals with mild cognitive impairment." Alzheimer’s & Dementia: Translational Research & Clinical Interventions 6(1): n/a-n/a.
dc.identifier.issn2352-8737
dc.identifier.issn2352-8737
dc.identifier.urihttps://hdl.handle.net/2027.42/154645
dc.description.abstractIntroductionThe safety of predicting conversion from mild cognitive impairment (MCI) to Alzheimer’s disease (AD) dementia using apolipoprotein E (APOE) genotyping is unknown.MethodsWe randomized 114 individuals with MCI to receive estimates of 3‐year risk of conversion to AD dementia informed by APOE genotyping (disclosure arm) or not (non‐disclosure arm) in a non‐inferiority clinical trial. Primary outcomes were anxiety and depression scores. Secondary outcomes included other psychological measures.ResultsUpper confidence limits for randomization arm differences were 2.3 on the State Trait Anxiety Index and 0.5 on the Geriatric Depression Scale, below non‐inferiority margins of 3.3 and 1.0. Moreover, mean scores were lower in the disclosure arm than non‐disclosure arm for test‐related positive impact (difference: ‐1.9, indicating more positive feelings) and AD concern (difference: ‐0.3).DiscussionProviding genetic information to individuals with MCI about imminent risk for AD does not increase risks of anxiety or depression and may provide psychological benefits.
dc.publisherAcademic Press
dc.publisherWiley Periodicals, Inc.
dc.subject.otherrisk
dc.subject.othergenetic testing
dc.subject.otherhealth behavior
dc.subject.otherhumans
dc.subject.otherrandom allocation
dc.subject.otherrisk assessment
dc.subject.otherAlzheimer’s disease
dc.subject.otheranxiety
dc.subject.otherapolipoprotein E4
dc.subject.othercognitive dysfunction
dc.subject.otherdementia
dc.subject.otherdepression
dc.subject.otheremotions
dc.titleDisclosing genetic risk for Alzheimer’s dementia to individuals with mild cognitive impairment
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelNeurology and Neurosciences
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154645/1/trc212002_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154645/2/trc212002.pdf
dc.identifier.doi10.1002/trc2.12002
dc.identifier.sourceAlzheimer’s & Dementia: Translational Research & Clinical Interventions
dc.identifier.citedreferencePiaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SW. Reporting of noninferiority and equivalence randomized trials: an extension of the consort statement. JAMA. 2006; 295: 1152 ‐ 1160.
dc.identifier.citedreferenceFlinter F. Should we sequence everyone’s genome? No. BMJ. 2013; 346: f3132.
dc.identifier.citedreferenceKwon JM, Steiner RD. “I’m fine; I’m just waiting for my disease”: the new and growing class of presymptomatic patients. Neurology. 2011; 77: 522 ‐ 523.
dc.identifier.citedreferenceKeogh LA, Niven H, Rutstein A, Flander L, Gaff C, Jenkins M. Choosing not to undergo predictive genetic testing for hereditary colorectal cancer syndromes: expanding our understanding of decliners and declining. J Behav Med. 2017: 1 ‐ 12.
dc.identifier.citedreferenceOffit K. Genomic profiles for disease risk: predictive or premature. JAMA. 2008; 299: 1353 ‐ 1355.
dc.identifier.citedreferenceGoldman JS, Hahn SE, Catania JW, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med. 2011; 13: 597 ‐ 605.
dc.identifier.citedreferenceBerg JS, Khoury MJ, Evans JP. Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet Med. 2011; 13: 499 ‐ 504.
dc.identifier.citedreferenceVansenne F, Bossuyt PM, de Borgie CA. Evaluating the psychological effects of genetic testing in symptomatic patients: a systematic review. Genet Test Mol Biomarkers. 2009; 13: 555 ‐ 563.
dc.identifier.citedreferenceGreen RC, Roberts JS, Cupples LA, et al. Disclosure of APOE genotype for risk of Alzheimer’s disease. N Engl J Med. 2009; 361: 245 ‐ 254.
dc.identifier.citedreferenceGreen RC, Christensen KD, Cupples LA, et al. A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer’s disease. Alzheimers Dement. 2015; 11: 1222 ‐ 1230.
dc.identifier.citedreferenceChristensen KD, Roberts JS, Whitehouse PJ, et al. Disclosing pleiotropic effects during genetic risk assessment for Alzheimer disease. A randomized trial Ann Intern Med. 2016; 164: 155 ‐ 163.
dc.identifier.citedreferenceZallen DT. “Well, good luck with that”: reactions to learning of increased genetic risk for Alzheimer disease. Genet Med. 2018; 20: 1462 ‐ 1467.
dc.identifier.citedreferencePetersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018; 90: 126 ‐ 135.
dc.identifier.citedreferencePetersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol. 2009; 66: 1447 ‐ 1455.
dc.identifier.citedreferenceQian J, Wolters FJ, Beiser A, et al. APOE‐related risk of mild cognitive impairment and dementia for prevention trials: an analysis of four cohorts. PLoS Med. 2017; 14: e1002254.
dc.identifier.citedreferenceGuan Y, Roter DL, Erby LH, et al. Disclosing genetic risk of Alzheimer’s disease to cognitively impaired patients and visit companions: findings from the REVEAL Study. Patient Educ Couns. 2017; 100: 927 ‐ 935.
dc.identifier.citedreferenceGrundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004; 61: 59 ‐ 66.
dc.identifier.citedreferenceCreavin ST, Wisniewski S, Noel‐Storr AH, et al. Mini‐Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst Rev. 2016 ( 1 ): Cd011145.
dc.identifier.citedreferenceMarteau TM, Bekker H. The development of a six‐item short‐form of the state scale of the Spielberger State‐Trait Anxiety Inventory (STAI). Br J Clin Psychol. 1992; 31 ( Pt 3 ): 301 ‐ 306.
dc.identifier.citedreferenceAlmeida OP, Almeida SA. Short versions of the geriatric depression scale: a study of their validity for the diagnosis of a major depressive episode according to ICD‐10 and DSM‐IV. Int J Geriatr Psychiatry. 1999; 14: 858 ‐ 865.
dc.identifier.citedreferenceSheikh JI, Yesavage JA. Recent evidence and development of a shorter version. In: Brink TL, ed. Clinical Gerontology: A Guide to Assessment and Intervention. New York: The Haworth Press; 1986: 165 ‐ 173.
dc.identifier.citedreferenceBunevicius A, Staniute M, Brozaitiene J, Pop VJM, Neverauskas J, Bunevicius R. Screening for anxiety disorders in patients with coronary artery disease. Health Qual Life Outcomes. 2013; 11: 37.
dc.identifier.citedreferenceGrant KA, McMahon C, Austin MP. Maternal anxiety during the transition to parenthood: a prospective study. J Affect Disord. 2008; 108: 101 ‐ 111.
dc.identifier.citedreferenceHorowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979; 41: 209 ‐ 218.
dc.identifier.citedreferenceChung WW, Chen CA, Cupples LA, et al. A new scale measuring psychologic impact of genetic susceptibility testing for Alzheimer disease. Alzheimer Dis Assoc Disord. 2009; 23: 50 ‐ 56.
dc.identifier.citedreferenceYip P, Cheung Y. Quick assessment of hopelessness: a cross‐sectional study. Health Qual Life Outcomes. 2006; 4: 13.
dc.identifier.citedreferenceChristensen KD, Roberts JS, Zikmund‐Fisher BJ, et al. Associations between self‐referral and health behavior responses to genetic risk information. Genome Med. 2015; 7: 10.
dc.identifier.citedreferenceGooding HC, Linnenbringer EL, Burack J, Roberts JS, Green RC, Biesecker BB. Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Patient Educ Couns. 2006; 64: 259 ‐ 267.
dc.identifier.citedreferenceLinnenbringer E, Roberts JS, Hiraki S, Cupples LA, Green RC. “I know what you told me, but this is what I think:” perceived risk of Alzheimer disease among individuals who accurately recall their genetics‐based risk estimate. Genet Med. 2010; 12: 219 ‐ 227.
dc.identifier.citedreferenceHeshka JT, Palleschi C, Howley H, Wilson B, Wells PS. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med. 2008; 10: 19 ‐ 32.
dc.identifier.citedreferenceKahan B, Morris T. Assessing potential sources of clustering in individually randomised trials. BMC Med Res Methodol. 2013; 13: 58.
dc.identifier.citedreferenceFitzmaurice GM. Applied Longitudinal Analysis. Hoboken, NJ: John Wiley & Sons; 2004.
dc.identifier.citedreferenceWalker E, Nowacki AS. Understanding equivalence and noninferiority testing. J Gen Intern Med. 2011; 26: 192 ‐ 196.
dc.identifier.citedreferenceChristensen KD, Uhlmann WR, Roberts JS, et al. A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genet Med. 2018; 20: 132 ‐ 141.
dc.identifier.citedreferenceBrodersen NH, Sutton S, Goff S, Hodgson SV, Thomas HJ. Anticipated reactions to genetic testing for hereditary non‐polyposis colorectal cancer susceptibility. Clin Genet. 2004; 66: 437 ‐ 444.
dc.identifier.citedreferenceWiggins S, Whyte P, Huggins M, et al. The psychological consequences of predictive testing for Huntington’s disease. Canadian Collaborative Study of Predictive Testing. N Engl J Med. 1992; 327: 1401 ‐ 1405.
dc.identifier.citedreferenceVandenberghe R, Rinne JO, Boada M, et al. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016; 8: 18.
dc.identifier.citedreferenceDoostparast Torshizi A, Wang K. Next‐generation sequencing in drug development: target identification and genetically stratified clinical trials. Drug Discov Today. 2018; 23: 1776 ‐ 1783.
dc.identifier.citedreferenceCalero O, Garcia‐Albert L, Rodriguez‐Martin A, Veiga S, Calero M. A fast and cost‐effective method for apolipoprotein E isotyping as an alternative to APOE genotyping for patient screening and stratification. Sci Rep. 2018; 8: 5969.
dc.identifier.citedreferencePerkins BA, Caskey CT, Brar P, et al. Precision medicine screening using whole‐genome sequencing and advanced imaging to identify disease risk in adults. Proc Natl Acad Sci U S A. 2018; 115: 3686 ‐ 3691.
dc.identifier.citedreferenceFood and Drug Administration. Evaluation of automatic class III designation for the 23andMe Personal Genome Service (PGS) genetic health risk test for hereditary thrombophilia, alpha‐1 antitrypsin deficiency, Alzheimer’s disease, Parkinson’s disease,Gaucher disease type 1, factor XI deficiency, celiac disease, G6PD deficiency, hereditary hemochromatosis and early‐onset primary dystonia. Decision summary. 2017.
dc.identifier.citedreferenceRoberts JS, Gornick MC, Carere DA, Uhlmann WR, Ruffin MT, Green RC. Direct‐to‐consumer genetic testing: user motivations, decision making, and perceived utility of results. Public Health Genom. 2017; 20: 36 ‐ 45.
dc.identifier.citedreferenceSherman K, Shaw LK, Champion K, Caldeira F, McCaskill M. The effect of disease risk probability and disease type on interest in clinic‐based versus direct‐to‐consumer genetic testing services. J Behav Med. 2015; 38: 706 ‐ 714.
dc.identifier.citedreferenceRoberts JS, Christensen KD, Green RC. Using Alzheimer’s disease as a model for genetic risk disclosure: implications for personal genomics. Clin Genet. 2011; 80: 407 ‐ 414.
dc.identifier.citedreferenceGallagher D, Coen R, Kilroy D, et al. Anxiety and behavioural disturbance as markers of prodromal Alzheimer’s disease in patients with mild cognitive impairment. Int J Geriatr Psychiatry. 2011; 26: 166 ‐ 172.
dc.identifier.citedreferenceGuan Y, Roter DL, Erby LH, et al. Communication predictors of patient and companion satisfaction with Alzheimer’s genetic risk disclosure. J Health Commun. 2018; 23: 807 ‐ 814.
dc.identifier.citedreferenceBiesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med. 2014; 370: 2418 ‐ 2425.
dc.identifier.citedreferenceGreen RC, Rehm HL, Kohane IS. Clinical genome sequencing. In: Ginsberg GS, Willard HF, eds. Genomic and Personalized Medicine. San Diego: Academic Press; 2013: 102 ‐ 122.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
trc212002_am.pdf
Size:
1.131MB
Format:
PDF
View/Open
Name:
trc212002.pdf
Size:
1.076MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.